SGLT-2 Inhibitors Market Revenue to Attain USD 29.50 Bn by 2033

30 Oct 2025

Share :

Table of Content

1. SGLT-2 Inhibitors Market Revenue and Trends 2025 to 2033 2. What are the key factors surging the growth of the market? 3. Segment Insights: 4. Regional Insights: 5. SGLT-2 Inhibitors Market Coverage

SGLT-2 Inhibitors Market Revenue and Trends 2025 to 2033

The global SGLT-2 inhibitors market revenue reached USD 18.18 billion in 2025 and is predicted to attain around USD 29.50 billion by 2033 with a CAGR of 6.24%. The market is growing due to expanding indications beyond glucose control, particularly for heart failure and chronic kidney disease, coupled with increasing global prevalence of type 2 diabetes and supportive clinical guideline updates.

What are the key factors surging the growth of the market?

The SGLT-2 inhibitors market is experiencing rapid growth due to several factors. Initially, the global prevalence of type 2 diabetes, particularly among the elderly and in rapidly developing countries, is leading to a substantial patient base requiring treatment. Secondly, robust clinical trial data consistently demonstrate that SGLT-2 inhibitors effectively improve glycemic control, alongside providing cardiovascular and renal advantages, including a reduction in heart failure hospitalizations and slowing the advancement of chronic kidney disease.

Thirdly, evolving clinical policies are expanding regulatory approvals and guideline recommendations, supporting the use of these medications at earlier stages of the disease and for non-diabetic populations. Fourthly, improved accessibility to these medications, through generics, cost negotiations, and a growing focus on health policies aimed at minimizing complications, is fostering better affordability and acceptance within numerous healthcare systems.

Segment Insights:

• By drug, the Jardiance (empagliflozin) segment dominated the market in 2024, due to its favorable cardiovascular and renal outcome profile, making it a preferred choice among prescribers.
• By indication, the type 2 diabetes segment held the largest market share in 2024, owing to the high global prevalence of the disease and the fact that it remains the primary approved indication for SGLT-2 inhibitors worldwide.
• By distribution channel, the hospital pharmacies segment led the market in 2024, because of the concentration of initial diagnoses and treatment initiation for diabetes, heart failure, and chronic kidney disease (CKD) in hospital settings, where formulary decisions are often made prior to outpatient care.

Regional Insights:

North America dominated the global SGLT-2 inhibitors market in 2024, driven by a higher prevalence of type 2 diabetes, a well-developed healthcare infrastructure, early regulatory approvals, and supportive reimbursement policies. The U.S. accounts for the majority of revenue within North America, with payers and guidelines increasingly incorporating SGLT-2 inhibitors for various indications. The growing awareness and clinical use of these inhibitors for cardiovascular and renal diseases further solidify the region's dominance.

Asia Pacific is expected to experience the fastest growth in the market. This is mainly due to the rising prevalence of type 2 diabetes, a growing middle class, improved healthcare access, and the increasing inclusion of SGLT-2 inhibitors on national formularies, particularly in India and China. Empagliflozin (Jardiance) has already become a prominent treatment option within the pediatric setting. The inclusion of these inhibitors in national formularies, especially in countries like India and China, is boosting their use.

SGLT-2 Inhibitors Market Coverage

Recent Development:

• In July 2025, Boehringer Ingelheim reported that Jardiance® (empagliflozin) generated approximately €4.3 billion in global sales during the first half of 2025 and highlighted that the company is advancing several late-stage therapies in its cardio-renal-metabolic portfolio. 

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7040

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344